Thus structural modelling of the all likely pathogenic USP9X-female variants located in the catalytic domain provides rationale for disrupted catalytic activity and/or ubiquitin binding, and is supported by analogous mechanisms of several proximal predicted deleterious variants arising in cancer. This evidence concerns the gene USP9X and cancer.